PURPOSE: Early-onset sepsis (EOS) is one of the main causes for the admission of newborns to the neonatal intensive care unit. However, traditional infection markers are poor diagnostic markers of EOS. Pancreatic stone protein (PSP) is a promising sepsis marker in adults. The aim of this study was to investigate whether determining PSP improves the diagnosis of EOS in comparison with other infection markers. METHODS: This was a prospective multicentre study involving 137 infants with a gestational age of >34 weeks who were admitted with suspected EOS. PSP, procalcitonin (PCT), soluble human triggering receptor expressed on myeloid cells-1 (sTREM-1), macrophage migration inhibitory factor (MIF) and C-reactive protein (CRP) were measured at admission. Receiver-operating characteristic (ROC) curve analysis was performed. RESULTS: The level of PSP in infected infants was significantly higher than that in uninfected ones (median 11.3 vs. 7.5 ng/ml, respectively; p = 0.001). The ROC area under the curve was 0.69 [95 % confidence interval (CI) 0.59-0.80; p < 0.001] for PSP, 0.77 (95 % CI 0.66-0.87; p < 0.001) for PCT, 0.66 (95 % CI 0.55-0.77; p = 0.006) for CRP, 0.62 (0.51-0.73; p = 0.055) for sTREM-1 and 0.54 (0.41-0.67; p = 0.54) for MIF. PSP independently of PCT predicted EOS (p < 0.001), and the use of both markers concomitantly significantly increased the ability to diagnose EOS. A bioscore combining PSP (>9 ng/ml) and PCT (>2 ng/ml) was the best predictor of EOS (0.83; 95 % CI 0.74-0.93; p < 0.001) and resulted in a negative predictive value of 100 % and a positive predictive value of 71 %. CONCLUSIONS: In this prospective study, the diagnostic performance of PSP and PCT was superior to that of traditional markers and a combination bioscore improved the diagnosis of sepsis. Our findings suggest that PSP is a valuable biomarker in combination with PCT in EOS.
RCT Entities:
PURPOSE: Early-onset sepsis (EOS) is one of the main causes for the admission of newborns to the neonatal intensive care unit. However, traditional infection markers are poor diagnostic markers of EOS. Pancreatic stone protein (PSP) is a promising sepsis marker in adults. The aim of this study was to investigate whether determining PSP improves the diagnosis of EOS in comparison with other infection markers. METHODS: This was a prospective multicentre study involving 137 infants with a gestational age of >34 weeks who were admitted with suspected EOS. PSP, procalcitonin (PCT), soluble human triggering receptor expressed on myeloid cells-1 (sTREM-1), macrophage migration inhibitory factor (MIF) and C-reactive protein (CRP) were measured at admission. Receiver-operating characteristic (ROC) curve analysis was performed. RESULTS: The level of PSP in infected infants was significantly higher than that in uninfected ones (median 11.3 vs. 7.5 ng/ml, respectively; p = 0.001). The ROC area under the curve was 0.69 [95 % confidence interval (CI) 0.59-0.80; p < 0.001] for PSP, 0.77 (95 % CI 0.66-0.87; p < 0.001) for PCT, 0.66 (95 % CI 0.55-0.77; p = 0.006) for CRP, 0.62 (0.51-0.73; p = 0.055) for sTREM-1 and 0.54 (0.41-0.67; p = 0.54) for MIF. PSP independently of PCT predicted EOS (p < 0.001), and the use of both markers concomitantly significantly increased the ability to diagnose EOS. A bioscore combining PSP (>9 ng/ml) and PCT (>2 ng/ml) was the best predictor of EOS (0.83; 95 % CI 0.74-0.93; p < 0.001) and resulted in a negative predictive value of 100 % and a positive predictive value of 71 %. CONCLUSIONS: In this prospective study, the diagnostic performance of PSP and PCT was superior to that of traditional markers and a combination bioscore improved the diagnosis of sepsis. Our findings suggest that PSP is a valuable biomarker in combination with PCT in EOS.
Authors: Barbara J Stoll; Nellie I Hansen; Pablo J Sánchez; Roger G Faix; Brenda B Poindexter; Krisa P Van Meurs; Matthew J Bizzarro; Ronald N Goldberg; Ivan D Frantz; Ellen C Hale; Seetha Shankaran; Kathleen Kennedy; Waldemar A Carlo; Kristi L Watterberg; Edward F Bell; Michele C Walsh; Kurt Schibler; Abbot R Laptook; Andi L Shane; Stephanie J Schrag; Abhik Das; Rosemary D Higgins Journal: Pediatrics Date: 2011-04-25 Impact factor: 7.124
Authors: T Calandra; B Echtenacher; D L Roy; J Pugin; C N Metz; L Hültner; D Heumann; D Männel; R Bucala; M P Glauser Journal: Nat Med Date: 2000-02 Impact factor: 53.440
Authors: Lucas Boeck; Rolf Graf; Philippe Eggimann; Hans Pargger; Dimitri A Raptis; Nicholas Smyrnios; Nehal Thakkar; Martin Siegemund; Janko Rakic; Michael Tamm; Daiana Stolz Journal: Chest Date: 2011-08-11 Impact factor: 9.410
Authors: Evridiki K Vouloumanou; Eleni Plessa; Drosos E Karageorgopoulos; Elpis Mantadakis; Matthew E Falagas Journal: Intensive Care Med Date: 2011-03-05 Impact factor: 17.440
Authors: Dirk Bassler; Barbara J Stoll; Barbara Schmidt; Elizabeth V Asztalos; Robin S Roberts; Charlene M T Robertson; Reg S Sauve Journal: Pediatrics Date: 2009-01 Impact factor: 7.124
Authors: Markus P Radsak; Christian Taube; Philipp Haselmayer; Stefan Tenzer; Helmut R Salih; Rainer Wiewrodt; Roland Buhl; Hansjörg Schild Journal: Clin Dev Immunol Date: 2007
Authors: Thierry Roger; Anina Schneider; Manuela Weier; Fred C G J Sweep; Didier Le Roy; Jürgen Bernhagen; Thierry Calandra; Eric Giannoni Journal: Proc Natl Acad Sci U S A Date: 2016-02-08 Impact factor: 11.205
Authors: Luregn J Schlapbach; Eric Giannoni; Sven Wellmann; Martin Stocker; Roland A Ammann; Rolf Graf Journal: BMC Anesthesiol Date: 2015-11-20 Impact factor: 2.217
Authors: Anwar A Rass; Mohamed A Talat; Mohamed A Arafa; Hosam F El-Saadany; Ezzat K Amin; Mohamed Mohamed Abdelsalam; Mona A Mansour; Naglaa A Khalifa; Lamiaa Mahmoud Kamel Journal: Biomed Res Int Date: 2016-09-05 Impact factor: 3.411